Gilead reported quarterly profits and income that beat analysts' ' expectations, boosted by sales of its drugs in Japan. World News & & Analysis
Read More »Gilead stock drops on Sovaldi revenue miss
Tuesday that revenue of its Hepatitis C drug gilead Sciences reported, Sovaldi, fell 20 percent from the last quarter nearly. World News & Analysis
Read More »Why Merck’s Idenix package is bad reports for Gilead
Analysts point out there's additional to Merck's curiosity about Idenix than its medicine portfolio-and that's the main reason Gilead's shares will be lower. Top News & Analysis
Read More »